127 related articles for article (PubMed ID: 38520745)
21. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
22. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
[TBL] [Abstract][Full Text] [Related]
23. First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study.
Tsukita Y; Inoue A
Jpn J Clin Oncol; 2022 Apr; ():. PubMed ID: 35446957
[TBL] [Abstract][Full Text] [Related]
24. Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Chang HC; Huang KT; Tseng CC; Chen YM; Lai CH; Chang YP; Chen YC; Chuang HY; Wang CC
Thorac Cancer; 2023 Nov; 14(32):3217-3225. PubMed ID: 37704454
[TBL] [Abstract][Full Text] [Related]
25. Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study.
Wang CC; Lai CH; Chang YP; Chang HC; Tseng CC; Huang KT; Lin MC
Thorac Cancer; 2021 Dec; 12(23):3263-3272. PubMed ID: 34704378
[TBL] [Abstract][Full Text] [Related]
26. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
[TBL] [Abstract][Full Text] [Related]
27. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
29. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
30. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
31. Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib
Moser SS; Apter L; Solomon J; Chodick G; Wollner M; Siegelmann-Danieli N
Anticancer Res; 2024 Jan; 44(1):257-265. PubMed ID: 38159972
[TBL] [Abstract][Full Text] [Related]
32. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Cheema P; Cho BC; Freitas H; Provencio M; Chen YM; Kim SW; Wu YL; Passaro A; Martin C; Tiseo M; Chang GC; Park K; Solomon B; Burghuber O; Laskin J; Wang Z; Lee SY; Hu Y; Vansteenkiste J; Zhang HL; Hanrahan E; Geldart T; Taylor R; Servidio L; Li J; Marinis F
Future Oncol; 2023 Jan; 19(1):61-75. PubMed ID: 36656302
[TBL] [Abstract][Full Text] [Related]
33. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Remon J; Besse B; Aix SP; Callejo A; Al-Rabi K; Bernabe R; Greillier L; Majem M; Reguart N; Monnet I; Cousin S; Garrido P; Robinet G; Garcia Campelo R; Madroszyk A; Mazières J; Curcio H; Wasąg B; Pretzenbacher Y; Fournier B; Dingemans AC; Dziadziuszko R
Ann Oncol; 2023 May; 34(5):468-476. PubMed ID: 36863484
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.
Li W; Qian L; Li W; Chen X; He H; Tian H; Zhao Y; Wang X; Cui J
Exp Ther Med; 2021 Apr; 21(4):343. PubMed ID: 33732316
[TBL] [Abstract][Full Text] [Related]
35. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial.
Yu HA; Schoenfeld AJ; Makhnin A; Kim R; Rizvi H; Tsui D; Falcon C; Houck-Loomis B; Meng F; Yang JL; Tobi Y; Heller G; Ahn L; Hayes SA; Young RJ; Arcila ME; Berger M; Chaft JE; Ladanyi M; Riely GJ; Kris MG
JAMA Oncol; 2020 Jul; 6(7):1048-1054. PubMed ID: 32463456
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.
Hung LJ; Hsu PC; Yang CT; Kuo CS; Chang JW; Huang CY; Chang CF; Wu CE
Aging (Albany NY); 2024 Jan; 16(1):550-567. PubMed ID: 38194721
[TBL] [Abstract][Full Text] [Related]
37. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Alós-Almiñana M; Cortijo J
J Comp Eff Res; 2019 Aug; 8(11):853-863. PubMed ID: 31478399
[No Abstract] [Full Text] [Related]
38. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
[TBL] [Abstract][Full Text] [Related]
39. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
[TBL] [Abstract][Full Text] [Related]
40. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]